<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02501538</url>
  </required_header>
  <id_info>
    <org_study_id>012015-051</org_study_id>
    <nct_id>NCT02501538</nct_id>
  </id_info>
  <brief_title>Continuous Diffusion of Oxygen (CDO) Treatment for Healing of Diabetic Foot Ulcers</brief_title>
  <acronym>EO2</acronym>
  <official_title>Continuous Diffusion of Oxygen (CDO) Treatment for Healing of Diabetic Foot Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study. Maximum 30 subjects with a diabetic foot ulcer (DFU) or surgical foot&#xD;
      wound will be consented in order to have 20 eligible subjects who will be enrolled and&#xD;
      completed the study. Study duration will be three weeks. Patients will be consented and&#xD;
      undergo debridement as standard of care at day 0. Ankle-Brachial Index (ABI), Monofilament&#xD;
      Sensory Test and Vibration Perception Threshold(VPT) test will be performed only at day 0.&#xD;
      Tissue samples will be taken at this visit during standard of care wound debridement and&#xD;
      these tissue samples of the wound would normally be removed as part of routine debridement.&#xD;
      These tissue samples of the wound will be used for gene expression and bacterial&#xD;
      analysis(research). The patient will then receive topical oxygen therapy using the&#xD;
      Transcutaneous O2 device (research) with moist wound dressings for 21 days. Moist wound&#xD;
      dressings are used as standard of care. Treatment will be initiated during Screening/Baseline&#xD;
      visit(day 0) after routine wound debridement, and patient will receive instructions for home&#xD;
      use of the device. The patient will be seen for routine wound debridement at days 7, 14, and&#xD;
      21 with a study window of 5 days., Digital photos of the wound, and vascular evaluations&#xD;
      (Transcutaneous oxygen measurements and Hyperspectral imaging. will be performed at each&#xD;
      study visit(research). Tissue samples will be taken during standard of care wound debridement&#xD;
      at every study visit. Results of the data analysis from this project will be used to inform&#xD;
      the design of a larger randomized clinical trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients seen at the University of Texas (UT) Southwestern Wound Clinic with a diabetic foot&#xD;
      wound will be identified, consented, and screened for the study. Upon signing consent,&#xD;
      patients will be assigned a unique screening number. The screening number given to the first&#xD;
      patient will be 01 and increasing sequentially with each subject screened. Screened subjects&#xD;
      will be entered onto a screening log. Once a number is assigned it cannot be re-assigned to&#xD;
      another subject.&#xD;
&#xD;
      At Day 0, a vascular evaluation including ABI, Sensilase, Transcutaneous oxygen measurements,&#xD;
      and hyperspectral imaging will be performed. Monofilament Sensory Test and Vibration&#xD;
      Perception Threshold(VPT) test will also be performed at day 0.Patients will undergo standard&#xD;
      of care wound debridement. Tissue samples will be taken routinely as standard of care. A&#xD;
      wound assessment will be performed, including the debridement as standard of care, wound&#xD;
      measurements, and digital photos. Gene expression and bacterial analysis will be performed on&#xD;
      tissue samples. After tests are performed, patient will receive topical oxygen therapy using&#xD;
      the Transcutaneous O2 device with moist wound dressings. Moist wound dressings are used as&#xD;
      standard of care. Patient will receive instructions to continue treatment at home.&#xD;
&#xD;
      Patient will return for an appointment at days 7, 14, and 21, where vascular assessment&#xD;
      (Sensilase, Transcutaneous oxygen measurements, Hyperspectral imaging) ,wound assessment&#xD;
      (wound measurements, digital photos and acetate tracings) and tissue sampling will be&#xD;
      performed following standard of care debridement, Patient will cease topical oxygen treatment&#xD;
      at day 21, and study will be concluded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Actual">January 10, 2020</completion_date>
  <primary_completion_date type="Actual">January 10, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tissue Oxygenation as Measured by Hyperspectral Imaging</measure>
    <time_frame>21 days</time_frame>
    <description>Hyperspectral (HyperMed, Inc.) images were taken for evaluation of tissue oxygenation following debridement at Visit 1 (day 0), visit 2 (day 7), visit 3 (day 14), visit 4 (day 21). Two images were taken of the study foot - one of the plantar surface and one of the dorsal surface to evaluate the oxygenation of the entire foot. Measurements of oxygenated hemoglobin are generated by the camera for each image. Results are reported in aggregate as mean/standard error for all time points.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tissue Perfusion as Measured by TCPO2</measure>
    <time_frame>21 days</time_frame>
    <description>Transcutaneous oxygen pressure (TCPO2) was measured at visit 1 (day 0), visit 2 (day 7), visit 3 (day 14), visit 4 (day 21) to assess perfusion of the tissue. This is measured at the medial and lateral foot to include both major blood vessels to the foot. Reported here as aggregate mean over all time points.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Levels of Growth Factors and Cytokines Involved in Wound Healing</measure>
    <time_frame>21 days</time_frame>
    <description>Comparison of measurements inflammatory cytokines: Interleukin 6 (IL-6), Interleukin 8 (IL-8), tumor necrosis factor (TNF)-α and growth factors: vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF), insulin derived growth factor (IGF), transforming growth factor beta (TGF)-β. These are reported as log fold change by delta delta ct.&#xD;
Evaluated from tissue samples obtained at visit 1 (day 0), visit 2 (day 7), visit 3 (day 14), visit 4 (day 21).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate Changes in Bacterial Infection</measure>
    <time_frame>21 days</time_frame>
    <description>Tissue samples sent for 16s rRNA quantitative culture. Reported in aggregate for each visit that corresponds to Visit 1 (day 0), visit 2 (day 7), visit 3 (day 14), visit 4 (day 21).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Wound Area Reduction</measure>
    <time_frame>21 days</time_frame>
    <description>Percent change of the wound area (measured in cm^2) of visit 2 (day 7), visit 3 (day 14), and visit 4 (day 21) compared to baseline.&#xD;
Percent area reduction = initial surface area (length in cm x width in cm) minus current surface area (length in cm x width in cm), divided by initial surface area. multiplied by 100 to get percentage.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Foot Ulcer, Diabetic</condition>
  <arm_group>
    <arm_group_label>Transcutaneous O2 device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continuous diffusion of oxygen (CDO) (topical oxygen) therapy, which will be administered using a portable device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcutaneous O2 device</intervention_name>
    <description>A portable device that delivers continuous diffusion of oxygen.</description>
    <arm_group_label>Transcutaneous O2 device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects of all races and ethnicities, age 18-89&#xD;
&#xD;
          -  Diagnosis of diabetes mellitus&#xD;
&#xD;
          -  Has a diabetic foot ulcer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  End-stage renal disease (ESRD)&#xD;
&#xD;
          -  Has untreated foot ulcer at time of study&#xD;
&#xD;
          -  HIV, hepatitis, autoimmune disease, Systemic lupus erythematous (SLE), Raynaud's&#xD;
             disease&#xD;
&#xD;
          -  Ankle-Brachial Index (ABI) &lt; 0.4&#xD;
&#xD;
          -  Unable or unwilling to provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence A Lavery, DPM</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 1, 2015</study_first_submitted>
  <study_first_submitted_qc>July 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2015</study_first_posted>
  <results_first_submitted>May 27, 2020</results_first_submitted>
  <results_first_submitted_qc>July 30, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 13, 2020</results_first_posted>
  <last_update_submitted>July 30, 2020</last_update_submitted>
  <last_update_submitted_qc>July 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Larry Lavery</investigator_full_name>
    <investigator_title>Lawrence A Lavery, DPM Study Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 25, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT02501538/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Transcutaneous O2 Device</title>
          <description>Continuous diffusion of oxygen (CDO) (topical oxygen) therapy, which will be administered using a portable device.&#xD;
Transcutaneous O2 device: A portable device that delivers continuous diffusion of oxygen.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Transcutaneous O2 Device</title>
          <description>Continuous diffusion of oxygen (CDO) (topical oxygen) therapy, which will be administered using a portable device.&#xD;
Transcutaneous O2 device: A portable device that delivers continuous diffusion of oxygen.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tissue Oxygenation as Measured by Hyperspectral Imaging</title>
        <description>Hyperspectral (HyperMed, Inc.) images were taken for evaluation of tissue oxygenation following debridement at Visit 1 (day 0), visit 2 (day 7), visit 3 (day 14), visit 4 (day 21). Two images were taken of the study foot - one of the plantar surface and one of the dorsal surface to evaluate the oxygenation of the entire foot. Measurements of oxygenated hemoglobin are generated by the camera for each image. Results are reported in aggregate as mean/standard error for all time points.</description>
        <time_frame>21 days</time_frame>
        <population>There was no control arm for this study. For analysis, groups were analyzed as &quot;healer&quot; and &quot;nonhealer.&quot; Healers are defined by those patients who achieved a 50% wound area reduction in the study time frame and are likely to heal within 12 weeks. Nonhealers did not reach a 50% wound area reduction in the study time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Transcutaneous O2 Device</title>
            <description>Continuous diffusion of oxygen (CDO) (topical oxygen) therapy, which will be administered using a portable device.&#xD;
Transcutaneous O2 device: A portable device that delivers continuous diffusion of oxygen.</description>
          </group>
        </group_list>
        <measure>
          <title>Tissue Oxygenation as Measured by Hyperspectral Imaging</title>
          <description>Hyperspectral (HyperMed, Inc.) images were taken for evaluation of tissue oxygenation following debridement at Visit 1 (day 0), visit 2 (day 7), visit 3 (day 14), visit 4 (day 21). Two images were taken of the study foot - one of the plantar surface and one of the dorsal surface to evaluate the oxygenation of the entire foot. Measurements of oxygenated hemoglobin are generated by the camera for each image. Results are reported in aggregate as mean/standard error for all time points.</description>
          <population>There was no control arm for this study. For analysis, groups were analyzed as &quot;healer&quot; and &quot;nonhealer.&quot; Healers are defined by those patients who achieved a 50% wound area reduction in the study time frame and are likely to heal within 12 weeks. Nonhealers did not reach a 50% wound area reduction in the study time frame.</population>
          <units>percent concentration of oxyhemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dorsal oxyhemoglobin - healer</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.58" spread="11.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dorsal oxyhemoglobin - nonhealer</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.91" spread="9.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plantar oxyhemoglobin - healer</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.33" spread="4.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plantar oxyhemoglobin - nonhealer</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.55" spread="5.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tissue Perfusion as Measured by TCPO2</title>
        <description>Transcutaneous oxygen pressure (TCPO2) was measured at visit 1 (day 0), visit 2 (day 7), visit 3 (day 14), visit 4 (day 21) to assess perfusion of the tissue. This is measured at the medial and lateral foot to include both major blood vessels to the foot. Reported here as aggregate mean over all time points.</description>
        <time_frame>21 days</time_frame>
        <population>There was no control arm for this study. For analysis, groups were analyzed as &quot;healer&quot; and &quot;nonhealer.&quot; Healers are defined by those patients who achieved a 50% wound area reduction in the study time frame and are likely to heal within 12 weeks. Nonhealers did not reach a 50% wound area reduction in the study time frame</population>
        <group_list>
          <group group_id="O1">
            <title>Transcutaneous Oxygen Measurements</title>
            <description>Medial and lateral foot measurements</description>
          </group>
        </group_list>
        <measure>
          <title>Tissue Perfusion as Measured by TCPO2</title>
          <description>Transcutaneous oxygen pressure (TCPO2) was measured at visit 1 (day 0), visit 2 (day 7), visit 3 (day 14), visit 4 (day 21) to assess perfusion of the tissue. This is measured at the medial and lateral foot to include both major blood vessels to the foot. Reported here as aggregate mean over all time points.</description>
          <population>There was no control arm for this study. For analysis, groups were analyzed as &quot;healer&quot; and &quot;nonhealer.&quot; Healers are defined by those patients who achieved a 50% wound area reduction in the study time frame and are likely to heal within 12 weeks. Nonhealers did not reach a 50% wound area reduction in the study time frame</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Transcutaneous oxygen - medial foot - healer</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.31" spread="4.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transcutaneous oxygen - medial foot - nonhealer</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.64" spread="3.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transcutaneous oxygen - lateral foot - healer</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.21" spread="3.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transcutaneous oxygen - lateral foot - nonhealer</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.31" spread="4.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Levels of Growth Factors and Cytokines Involved in Wound Healing</title>
        <description>Comparison of measurements inflammatory cytokines: Interleukin 6 (IL-6), Interleukin 8 (IL-8), tumor necrosis factor (TNF)-α and growth factors: vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF), insulin derived growth factor (IGF), transforming growth factor beta (TGF)-β. These are reported as log fold change by delta delta ct.&#xD;
Evaluated from tissue samples obtained at visit 1 (day 0), visit 2 (day 7), visit 3 (day 14), visit 4 (day 21).</description>
        <time_frame>21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cytokine and Growth Factor Measurement</title>
            <description>Measurement of cytokines</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Levels of Growth Factors and Cytokines Involved in Wound Healing</title>
          <description>Comparison of measurements inflammatory cytokines: Interleukin 6 (IL-6), Interleukin 8 (IL-8), tumor necrosis factor (TNF)-α and growth factors: vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF), insulin derived growth factor (IGF), transforming growth factor beta (TGF)-β. These are reported as log fold change by delta delta ct.&#xD;
Evaluated from tissue samples obtained at visit 1 (day 0), visit 2 (day 7), visit 3 (day 14), visit 4 (day 21).</description>
          <units>log fold change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-6 visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.68" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-6 Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.37" spread="5.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-6 Visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.24" spread="6.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-6 Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.12" spread="2.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL8 visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.97" spread="1.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL8 visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.12" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL8 visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.51" spread="2.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL8 visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.22" spread="2.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNFa visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.82" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNFa visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.17" spread="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNFa visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.03" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNFa visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.27" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.37" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.85" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.35" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.29" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PDGF visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PDGF visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.92" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PDGF visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.76" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PDGF visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.81" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGF1 visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.04" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGF1 visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.91" spread="9.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGF1 visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.47" spread="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGF1 visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.25" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TGFb visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.27" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TGFb visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.42" spread="3.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TGFb visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.65" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TGFb visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.96" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluate Changes in Bacterial Infection</title>
        <description>Tissue samples sent for 16s rRNA quantitative culture. Reported in aggregate for each visit that corresponds to Visit 1 (day 0), visit 2 (day 7), visit 3 (day 14), visit 4 (day 21).</description>
        <time_frame>21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Quantitative Bacterial Cultures</title>
            <description>Quantitative bacterial cultures by visit</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluate Changes in Bacterial Infection</title>
          <description>Tissue samples sent for 16s rRNA quantitative culture. Reported in aggregate for each visit that corresponds to Visit 1 (day 0), visit 2 (day 7), visit 3 (day 14), visit 4 (day 21).</description>
          <units>CFU/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137071.35" spread="204854.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="433719.88" spread="1009663.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="276842.20" spread="603627.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="598557.90" spread="2303848.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Wound Area Reduction</title>
        <description>Percent change of the wound area (measured in cm^2) of visit 2 (day 7), visit 3 (day 14), and visit 4 (day 21) compared to baseline.&#xD;
Percent area reduction = initial surface area (length in cm x width in cm) minus current surface area (length in cm x width in cm), divided by initial surface area. multiplied by 100 to get percentage.</description>
        <time_frame>21 days</time_frame>
        <population>There was no control arm for this study. For analysis, groups were analyzed as &quot;healer&quot; and &quot;nonhealer.&quot; Healers are defined by those patients who achieved a 50% wound area reduction in the study time frame and are likely to heal within 12 weeks. Nonhealers did not reach a 50% wound area reduction in the study time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Transcutaneous O2 Device</title>
            <description>Continuous diffusion of oxygen (CDO) (topical oxygen) therapy, which will be administered using a portable device.&#xD;
Transcutaneous O2 device: A portable device that delivers continuous diffusion of oxygen.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Wound Area Reduction</title>
          <description>Percent change of the wound area (measured in cm^2) of visit 2 (day 7), visit 3 (day 14), and visit 4 (day 21) compared to baseline.&#xD;
Percent area reduction = initial surface area (length in cm x width in cm) minus current surface area (length in cm x width in cm), divided by initial surface area. multiplied by 100 to get percentage.</description>
          <population>There was no control arm for this study. For analysis, groups were analyzed as &quot;healer&quot; and &quot;nonhealer.&quot; Healers are defined by those patients who achieved a 50% wound area reduction in the study time frame and are likely to heal within 12 weeks. Nonhealers did not reach a 50% wound area reduction in the study time frame.</population>
          <units>percent change of wound area (cm^2)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Wound area reduction - visit 1 - healers</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.75" spread="8.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wound area reduction - visit 3 - healers</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.64" spread="6.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wound area reduction - visits 4 - healers</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.91" spread="7.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wound area reduction - visit 2 - nonhealers</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.59" spread="6.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wound area reduction - visit 3 - nonhealers</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.07" spread="17.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ound area reduction- visit 4 - nonhealers</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.21" spread="14.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>21 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Transcutaneous O2 Device</title>
          <description>Continuous diffusion of oxygen (CDO) (topical oxygen) therapy, which will be administered using a portable device.&#xD;
Transcutaneous O2 device: A portable device that delivers continuous diffusion of oxygen.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Celluliltis</sub_title>
                <description>Unilateral leg cellulitis, nonstudy leg</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Abrasion</sub_title>
                <description>Abrasion from offloading boot</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Foot swelling</sub_title>
                <description>Swelling of study foot</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lawrence Lavery, DPM, MPH</name_or_title>
      <organization>UT Southwestern Medical Center at Dallas</organization>
      <phone>214-645-0544</phone>
      <email>Larry.Lavery@UTSouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

